Bionano Genomics, Inc. · NASDAQ:BNGO
Bionano Genomics — Q2 2021 Earnings Presentation
15 slides from Bionano Genomics's earnings presentation, Aug 4, 2021
Slide 1: Q2 Webcast and Call August 4, 2021
Q2 Webcast and Call August 4, 2021
Slide 2: Legal Disclaimer
2 Legal Disclaimer This presentation contains forward-looking statements. Forward-looking statements describe future expectations, plans, results or strategies and are generally preceded by terms such as “may,” “will,” “should,” “could,” “would,” “expects,” “plans,” “anticipates,” “believes,” “estim
Slide 3: Bionano Genomics: 3 Key Areas of Focus
3 To continuously innovate to bring new capabilities that accelerate throughput Bionano Genomics: 3 Key Areas of Focus In clinical research and discovery research markets where OGM complements any type of sequencing Through Bionano pivotal clinical studies and third- party support and advocacy Build
Slide 4: Q2 2021: Great Results and Execution
4 Q2 2021: Great Results and Execution Q2 New Applications in Prenatal Testing, Cancer Research & Development Presented 13 16 New Publications in Q2, the Most OGM Publications Ever in a Single Quarter Talks and Posters Saphyr Systems Shipped 121 total installed Advancing Go to Market – Bionano Data
Slide 5: Record Number of Presentations Featuring OGM Data at European Cytogenomics Association Conference
5 Record Number of Presentations Featuring OGM Data at the 2021 European Cytogenomics Association Conference from July 3 - 5 Institution Bionano's OGM Benefits Presented ・Improvement to patient treatment and prognostic accuracy for ALL ・100% concordance relative to standard of care w/ no false posit
Slide 6: Record Number of Presentations Featuring OGM Data at Cancer Genomics Consortium Annual Meeting
6 Record Number of Presentations Featuring OGM Data at the 2021 Cancer Genomics Consortium Annual Meeting from August 1 - 4 OGM Application Area Presenter Affiliation Presentation Title Solid Tumor Analysis Dr. Miriam Bornhorst Children's National Hospital Optical genome mapping reveals novel struct
Slide 7: Bionano Data Continues to Contribute to Advances in Research
7 Bionano Data Continues to Contribute to Advances in Research ALS Resolved mosaic repeat expansions Alzheimer’s Disease Identified deletions in CR1 Leukemia In 12 patients, found dozens of novel genes with recurring structural variants Hepatocellular Carcinoma Identified Hep B Virus insertion that
Slide 8: Advanced and Optimized the Performance of the Saphyr System for Adoption in Labs
8 Advanced and Optimized the Performance of the Saphyr System for Adoption in Labs to Support Development of Clinical Assays and LDTs Launched an LDT for whole genome analysis with OGM for constitutional genetic disease Developing LDTs for prenatal and solid tumor analysis Received PLA code KE
Slide 9: Clinical Affairs Summary
9 Clinical Affairs Summary Dr. Alka Chaubey CMO achaubey@bionanogenomics.com
Slide 10: Four Large Clinical Studies Getting Underway to Support Penetration of Target Markets
10 Four Large Clinical Studies Getting Underway to Support Penetration of our Target Markets & Support Potential Third-Party Reimbursement Constitutional - Prenatal - Constitutional - Pediatric - Oncology - Heme Malignancies - Oncology - Solid Tumor - Amnio & CVS Illustrate HOW Saphyr can help with
Slide 11: Financial Overview
11 Financial Overview Chris Stewart CFO cstewart@bionanogenomics.com
Slide 12: Q2 2021 – Financial Results and Key Highlights
12 Q2 2021 – Financial Results and Key Highlights • Total revenue was $3.9M, up 226% from Q2 2020 • Year-on-year revenue was up in all geographies and across both product and service revenue • BNGO is a member of the Russell 2000® Index Strong cash position with $333M to end Q2 2021 2Q21 $M, except
Slide 13: Summary
13 Summary R. Erik Holmlin CEO eholmlin@bionanogenomics.com
Slide 14: Key Anticipated Milestones Expected to Drive Value for BNGO
14 • Commercial release of prenatal assays for Saphyr and expansion of Saphyr’s menu of pediatric assays Key Anticipated Milestones Expected to Drive Value for BNGO 3Q Accreditation of Saphyr based LDTs for ALL & FSHD in certain EU markets 2Q 4Q • Interim publication of results from pediatric clin
Slide 15: Questions & Answers
Questions & Answers Contact: R. Erik Holmlin CEO eholmlin@bionanogenomics.com Chris Stewart CFO cstewart@bionanogenomics.com